Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation

Blood. 2002 Feb 1;99(3):1085-8. doi: 10.1182/blood.v99.3.1085.

Abstract

An unusually high incidence of acyclovir- and foscarnet-resistant herpes simplex virus (HSV) infection was noted after lymphocyte-depleted blood hematopoietic progenitor cell (HPC) transplantation from HLA-haploidentical family donors. Fourteen adults with hematologic malignancies underwent blood HPC transplantation from haploidentical family donors. Pheresis products were stringently depleted of T and B cells by immunomagnetic adsorption, and patients received no immunosuppression after transplantation. HSV reactivation occurred in all 7 evaluable HSV-1- or HSV-2-seropositive patients, at a median of 40 days after transplantation. Susceptibility testing of clinically resistant viral isolates demonstrated acyclovir resistance in all 5 cases tested. Second-line therapy produced only partial responses, and in vitro evidence of foscarnet resistance developed rapidly in all 3 patients treated with foscarnet. Healing of lesions coincided with T-cell recovery. The prolonged immunodeficiency associated with stringent lymphocyte depletion of the graft appears to strongly predispose to emergence of drug-resistant HSV. Furthermore, immune reconstitution is necessary for eradication of infection.

MeSH terms

  • Acyclovir / pharmacology
  • Adult
  • Antiviral Agents / pharmacology
  • Drug Resistance, Viral*
  • Female
  • Foscarnet / pharmacology
  • Haplotypes
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Herpes Simplex / etiology*
  • Histocompatibility
  • Humans
  • Incidence
  • Lymphocyte Depletion / adverse effects
  • Male
  • Middle Aged
  • Transplantation, Homologous / adverse effects
  • Transplantation, Homologous / immunology

Substances

  • Antiviral Agents
  • Foscarnet
  • Acyclovir